Balefire LLC Sells 12,141 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Balefire LLC cut its IQVIA stake by 73.7% in the second quarter, selling 12,141 shares and retaining 4,326 shares valued at approximately $836,000. Institutional investors overall own 89.62% of IQVIA.
• IQVIA reported quarterly EPS of $3.15, exceeding estimates of $3.03, while revenue rose 8.7% year over year to $4.37 billion. The company also authorized a $2 billion share-repurchase program covering up to 6.8% of outstanding shares.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $241.88. However, insiders have sold 12,913 shares worth roughly $3.1 million over the past 90 days.

Balefire LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 73.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,326 shares of the medical research company's stock after selling 12,141 shares during the quarter. Balefire LLC's holdings in IQVIA were worth $836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in shares of IQVIA by 17.1% during the 2nd quarter. GAMMA Investing LLC now owns 3,413 shares of the medical research company's stock worth $659,000 after buying an additional 498 shares during the period. Versant Capital Management Inc boosted its stake in IQVIA by 27.7% during the second quarter. Versant Capital Management Inc now owns 2,291 shares of the medical research company's stock worth $443,000 after acquiring an additional 497 shares in the last quarter. CX Institutional boosted its stake in IQVIA by 31.5% during the second quarter. CX Institutional now owns 2,340 shares of the medical research company's stock worth $452,000 after acquiring an additional 560 shares in the last quarter. Pacer Advisors Inc. increased its stake in IQVIA by 5,108.6% in the first quarter. Pacer Advisors Inc. now owns 729,043 shares of the medical research company's stock valued at $124,331,000 after purchasing an additional 715,046 shares in the last quarter. Finally, Lombard Odier Asset Management Europe Ltd increased its stake in IQVIA by 38.3% in the first quarter. Lombard Odier Asset Management Europe Ltd now owns 69,585 shares of the medical research company's stock valued at $11,867,000 after purchasing an additional 19,255 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Down 1.5%

NYSE IQV opened at $232.41 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The business has a fifty day simple moving average of $199.81 and a 200 day simple moving average of $186.59. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $251.36. The firm has a market capitalization of $38.26 billion, a P/E ratio of 28.84, a PEG ratio of 2.00 and a beta of 1.18.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the previous year, the firm earned $2.81 EPS. The business's revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a share buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on IQV shares. JPMorgan Chase & Co. raised their target price on IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Morgan Stanley reissued an "equal weight" rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Stifel Nicolaus upped their target price on IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Robert W. Baird boosted their price target on shares of IQVIA from $252.00 to $287.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $241.88.

Insider Activity

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. This represents a 19.23% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 12,913 shares of company stock worth $3,098,793. Corporate insiders own 1.70% of the company's stock.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source